Across TCGA pan-cancer cohorts, NLGN3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NLGN3 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher NLGN3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated NLGN3 expression acts as an unfavorable survival marker.

LIHC, LUAD, and PRAD are the cancer types where NLGN3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Median	III,IV	0.076	0.333	.003	21	view →
LUAD	OS	Median	All	0.141	0.788	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NLGN3 tumor-vs-normal RNA expression · all NLGN3 data types